Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156

Inclusion Criteria: * Healthy males aged 30 to 65 years inclusive * Body mass index (BMI) of 18.0 to 35.0 kg/m2 * Must be willing and able to communicate and participate in the whole study * Must have regular bowel movements * Must provide written informed consent * Must agree to adhere to contraception requirements Exclusion Criteria: * Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1 * Subjects who are, or are immediate family members of, a study site or sponsor employee * Evidence of current SARS-CoV-2 infection from results of diagnostic tests or from symptoms reported at screening or admission * History of any drug or alcohol abuse in the past 2 years * Regular alcohol consumption * A confirmed positive alcohol breath test at screening or admission * Current smokers and those who have smoked within the last 12 months. * Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months * Subjects with pregnant or lactating partners * Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. * Subjects who do not have suitable veins for multiple venepunctures/cannulation * Clinically significant abnormal clinical chemistry, haematology or urinalysis. Subjects with Gilbert's Syndrome are allowed. * Confirmed positive drugs of abuse test result * Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results * Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance (CLcr) of \<80 mL/min using the Cockcroft-Gault equation * History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder * Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients * Presence or history of clinically significant allergy requiring treatment. Hay fever is allowed unless it is active * Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood * Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day) in the 14 days before IMP administration. * Failure to satisfy the investigator of fitness to participate for any other reason